Aclarion Inc (ACON)vsNovartis AG ADR (NVS)
ACON
Aclarion Inc
$1.74
-1.14%
HEALTHCARE · Cap: $5.62M
NVS
Novartis AG ADR
$159.26
+3.59%
HEALTHCARE · Cap: $303.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 68477877% more annual revenue ($57.36B vs $83,770). NVS leads profitability with a 17.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 48/100 (D+).
ACON
Avoid33
out of 100
Grade: F
NVS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACON.
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$159.26
$63.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 30.5% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ACON
The strongest argument for ACON centers on Price/Book, Revenue Growth. Revenue growth of 30.5% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bear Case : ACON
The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Key Dynamics to Monitor
ACON profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
ACON carries more volatility with a beta of 1.21 — expect wider price swings.
ACON is growing revenue faster at 30.5% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 33/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aclarion Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Aclarion Inc (ACON) is an innovative healthcare technology company focused on transforming the diagnosis and management of musculoskeletal conditions through advanced non-invasive imaging and data analytics. Leveraging machine learning capabilities, Aclarion provides healthcare professionals with actionable insights that improve clinical outcomes while optimizing cost-effective treatment pathways. As a key player in the digital health arena, the company is positioned to address the growing demand for effective diagnostic solutions, thereby enhancing patient care and management in a rapidly evolving healthcare environment. Aclarion's commitment to improving patient outcomes places it at the forefront of future healthcare delivery advancements.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?